News Immunocore and GSK pick third cancer immunotherapy target Immunocore, one of UK biotech's brightest hopes, has selected a third target as part of its immuno-oncology partnership with GlaxoSmithKline.
News Immunocore's T-cell therapy could provide HIV cure Treatment promises cure by reactivating immune cells to kill latent HIV-infected cells.
R&D T-cell specialist Immunocore raises $320m in private finance Immunocore, a UK-based biotech specialising in T-cell receptor drugs has raised $320 million (£205 million), making it Europe's largest private life sciences financing.
Cancer Lilly and Immunocore collaborate on novel cancer therapies Eli Lilly and Immunocore have agreed to collaborate on R&D into novel T-cell-based cancer therapies.
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends